Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Department of Medical Microbiology and Parasitology, Faculty of Clinical Sciences, College of Health Sciences, Bayero University, Kano, PMB 3011 Kano State, Nigeria.
Asian Pac J Cancer Prev. 2020 Oct 1;21(10):2837-2846. doi: 10.31557/APJCP.2020.21.10.2837.
Background: Infection with an oncogenic type of human papillomavirus is a prerequisite for the development of precancerous cervical lesions and its subsequent progression to cervical cancer. With an alarming increase in the detection of other suspicious papillomavirus genotypes in both healthy and women with cervical lesions, there is a need for comprehensive data on cervical papillomavirus infection to address cervical cancer and other associated disease burden, especially in Sub-Sarahan Africa, where the bulk of the problem exists. The present study was conducted to develop comprehensive data on the prevalence and circulating genotypes of human papillomavirus in various risk categories in Nigeria. Methods: A systematic review and meta-analysis of peer-reviewed publications on cervical papillomavirus infection were performed. Relevant data were extracted from eligible studies published in PubMed, Web of Science, Embase, Scopus, and Google Scholar, from inception to July 31, 2019. The random-effect model was used to estimate the pooled prevalence. We identified 327 potential studies and pooled data from 18 studies, involving 5697 women aged 15-86 years. Results: The overall pooled prevalence of cervical papillomavirus infection was 42% (95%CI: 30-54%) in the general population and 37% (95%CI: 25-50%) among women living with HIV/AIDS, with the predominance of genotypes 16, 18, 31, 35, 52, 58 and 45. The highest prevalence was observed in teenagers and young adults and the second peak in women 50 years and above. Conclusion: The prevalence of cervical human papillomavirus infection is cumulatively high in Nigeria and HIV is a strong co-factor. We, therefore, strongly recommend the co-screening of human papillomavirus and cervical cancer and integration of the intervention strategy into the existing HIV-care guideline in Nigeria.
感染致癌型人乳头瘤病毒是宫颈癌前病变及其随后进展为宫颈癌的先决条件。在健康人群和患有宫颈病变的人群中,其他可疑型人乳头瘤病毒基因型的检出率均呈惊人上升趋势,因此需要全面了解宫颈人乳头瘤病毒感染情况,以应对宫颈癌和其他相关疾病负担,尤其是在宫颈癌负担最重的撒哈拉以南非洲地区。本研究旨在为尼日利亚不同风险人群的宫颈人乳头瘤病毒感染流行情况和循环基因型提供全面的数据。
对已发表的关于宫颈人乳头瘤病毒感染的同行评议文献进行系统综述和荟萃分析。从 Pubmed、Web of Science、Embase、Scopus 和 Google Scholar 等数据库中检索 2019 年 7 月 31 日前发表的关于宫颈人乳头瘤病毒感染的相关研究,提取合格研究的相关数据。使用随机效应模型来估计汇总患病率。我们共确定了 327 项潜在研究,并对 18 项研究的数据进行了汇总,共纳入了 5697 名年龄在 15-86 岁的女性。
普通人群中宫颈人乳头瘤病毒感染的总体汇总患病率为 42%(95%CI:30-54%),HIV 感染者中为 37%(95%CI:25-50%),优势基因型为 16、18、31、35、52、58 和 45。青少年和年轻成年女性的感染率最高,其次是 50 岁以上女性。
尼日利亚的宫颈人乳头瘤病毒感染率居高不下,且 HIV 是一个强有力的共同因素。因此,我们强烈建议对人乳头瘤病毒和宫颈癌进行联合筛查,并将干预策略纳入尼日利亚现有的 HIV 护理指南。